If Jemperli might effectively cure a biomarker-defined subset of rectal cancer patients why isn't pharma more interested?
Roche’s SCLC study is an unmitigated disaster, but investors holding out for success in NSCLC are thrown a crumb of comfort.
ILT3 blockade shows no monotherapy activity while a combo runs into toxicity issues, but Merck presses on.
After the latest roxadustat clanger a phase 3 interim analysis in pancreatic cancer becomes even more important for Fibrogen.
Aduhelm’s status as a commercial nonentity is confirmed, but what does the final coverage decision mean for follow-on amyloid-beta MAbs?
Roche awaits Tigit and Serd data, Lilly takes on obesity, and Glaxo and Pfizer race in RSV.